Cargando…

Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron 50 mg in Sexually Active Men With Bothersome Overactive Bladder Symptoms – A Multicenter, Randomized Study

PURPOSE: We evaluated the therapeutic effects on overactive bladder (OAB) symptoms and sexual function of behavioral therapy with or without mirabegron in sexually active male patients with OAB. Mirabegron, a selective β3 adrenoceptor agonist for the treatment of OAB, has been shown to induce corpus...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Chih-Chieh, Kuo, Hann-Chorng, Li, Jian-Ri, Chuang, Yao-Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Continence Society 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556431/
https://www.ncbi.nlm.nih.gov/pubmed/37798885
http://dx.doi.org/10.5213/inj.2346148.074
_version_ 1785116869812813824
author Lin, Chih-Chieh
Kuo, Hann-Chorng
Li, Jian-Ri
Chuang, Yao-Chi
author_facet Lin, Chih-Chieh
Kuo, Hann-Chorng
Li, Jian-Ri
Chuang, Yao-Chi
author_sort Lin, Chih-Chieh
collection PubMed
description PURPOSE: We evaluated the therapeutic effects on overactive bladder (OAB) symptoms and sexual function of behavioral therapy with or without mirabegron in sexually active male patients with OAB. Mirabegron, a selective β3 adrenoceptor agonist for the treatment of OAB, has been shown to induce corpus cavernosum relaxation. METHODS: In this 4-site, randomized controlled trial, 150 sexually active men with OAB were enrolled between June 2020 and May 2022. Participants were randomly allocated (1:2) into 2 treatment groups: (1) behavioral therapy alone (n = 50) and (2) a combination of mirabegron 50 mg daily and behavioral therapy (n = 100). The evaluation was based on the overactive bladder symptoms score (OABSS), the International Index of Erectile Function, the ejaculatory domain short form, the International Prostate Symptom Score, patient perception of bladder condition, quality of life, and urodynamic parameters. The therapeutic outcomes were assessed at baseline, 4 weeks, and 12 weeks. RESULTS: There were 65 patients (65%) in the combination subgroup and 36 patients in the behavioral therapy who completed all 12 weeks of treatment. Both groups had a statistically significant improvement in OABSS after 12 weeks of treatment. The combination therapy group achieved a statistically significant improvement in all 4 subscores of OABSS, however, the urinary frequency (P = 0.120) and urinary incontinence (P = 0.234) subscores in the behavioral therapy only group did not show a significant change. Additionally, the combination group had a significant improvement in functional bladder capacity, which was not seen in the behavioral therapy group. However, both groups did not have a significant change in erectile or ejaculatory function. CONCLUSIONS: Behavioral therapy combined with mirabegron had more significant impact on the improvement of OAB than behavior therapy alone. However, both groups did not have significant changes in erectile or ejaculatory function.
format Online
Article
Text
id pubmed-10556431
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Korean Continence Society
record_format MEDLINE/PubMed
spelling pubmed-105564312023-10-07 Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron 50 mg in Sexually Active Men With Bothersome Overactive Bladder Symptoms – A Multicenter, Randomized Study Lin, Chih-Chieh Kuo, Hann-Chorng Li, Jian-Ri Chuang, Yao-Chi Int Neurourol J Original Article PURPOSE: We evaluated the therapeutic effects on overactive bladder (OAB) symptoms and sexual function of behavioral therapy with or without mirabegron in sexually active male patients with OAB. Mirabegron, a selective β3 adrenoceptor agonist for the treatment of OAB, has been shown to induce corpus cavernosum relaxation. METHODS: In this 4-site, randomized controlled trial, 150 sexually active men with OAB were enrolled between June 2020 and May 2022. Participants were randomly allocated (1:2) into 2 treatment groups: (1) behavioral therapy alone (n = 50) and (2) a combination of mirabegron 50 mg daily and behavioral therapy (n = 100). The evaluation was based on the overactive bladder symptoms score (OABSS), the International Index of Erectile Function, the ejaculatory domain short form, the International Prostate Symptom Score, patient perception of bladder condition, quality of life, and urodynamic parameters. The therapeutic outcomes were assessed at baseline, 4 weeks, and 12 weeks. RESULTS: There were 65 patients (65%) in the combination subgroup and 36 patients in the behavioral therapy who completed all 12 weeks of treatment. Both groups had a statistically significant improvement in OABSS after 12 weeks of treatment. The combination therapy group achieved a statistically significant improvement in all 4 subscores of OABSS, however, the urinary frequency (P = 0.120) and urinary incontinence (P = 0.234) subscores in the behavioral therapy only group did not show a significant change. Additionally, the combination group had a significant improvement in functional bladder capacity, which was not seen in the behavioral therapy group. However, both groups did not have a significant change in erectile or ejaculatory function. CONCLUSIONS: Behavioral therapy combined with mirabegron had more significant impact on the improvement of OAB than behavior therapy alone. However, both groups did not have significant changes in erectile or ejaculatory function. Korean Continence Society 2023-09 2023-09-30 /pmc/articles/PMC10556431/ /pubmed/37798885 http://dx.doi.org/10.5213/inj.2346148.074 Text en Copyright © 2023 Korean Continence Society https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lin, Chih-Chieh
Kuo, Hann-Chorng
Li, Jian-Ri
Chuang, Yao-Chi
Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron 50 mg in Sexually Active Men With Bothersome Overactive Bladder Symptoms – A Multicenter, Randomized Study
title Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron 50 mg in Sexually Active Men With Bothersome Overactive Bladder Symptoms – A Multicenter, Randomized Study
title_full Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron 50 mg in Sexually Active Men With Bothersome Overactive Bladder Symptoms – A Multicenter, Randomized Study
title_fullStr Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron 50 mg in Sexually Active Men With Bothersome Overactive Bladder Symptoms – A Multicenter, Randomized Study
title_full_unstemmed Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron 50 mg in Sexually Active Men With Bothersome Overactive Bladder Symptoms – A Multicenter, Randomized Study
title_short Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron 50 mg in Sexually Active Men With Bothersome Overactive Bladder Symptoms – A Multicenter, Randomized Study
title_sort comparative study between behavior therapy and behavior therapy plus mirabegron 50 mg in sexually active men with bothersome overactive bladder symptoms – a multicenter, randomized study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556431/
https://www.ncbi.nlm.nih.gov/pubmed/37798885
http://dx.doi.org/10.5213/inj.2346148.074
work_keys_str_mv AT linchihchieh comparativestudybetweenbehaviortherapyandbehaviortherapyplusmirabegron50mginsexuallyactivemenwithbothersomeoveractivebladdersymptomsamulticenterrandomizedstudy
AT kuohannchorng comparativestudybetweenbehaviortherapyandbehaviortherapyplusmirabegron50mginsexuallyactivemenwithbothersomeoveractivebladdersymptomsamulticenterrandomizedstudy
AT lijianri comparativestudybetweenbehaviortherapyandbehaviortherapyplusmirabegron50mginsexuallyactivemenwithbothersomeoveractivebladdersymptomsamulticenterrandomizedstudy
AT chuangyaochi comparativestudybetweenbehaviortherapyandbehaviortherapyplusmirabegron50mginsexuallyactivemenwithbothersomeoveractivebladdersymptomsamulticenterrandomizedstudy